|
1
|
Ferguson BS, Rogatzki MJ, Goodwin ML, Kane
DA, Rightmire Z and Gladden LB: Lactate metabolism: Historical
context, prior misinterpretations, and current understanding. Eur J
Appl Physiol. 118:691–728. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liberti MV and Locasale JW: The warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Certo M, Tsai CH, Pucino V, Ho PC and
Mauro C: Lactate modulation of immune responses in inflammatory
versus tumour microenvironments. Nat Rev Immunol. 21:151–161. 2021.
View Article : Google Scholar
|
|
4
|
Syed M, Kammala AK, Callahan B,
Oskeritzian CA and Subramanian H: Lactic acid suppresses MRGPRX2
mediated mast cell responses. Cell Immunol. 368:1044222021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Souto-Carneiro MM, Klika KD, Abreu MT,
Meyer AP, Saffrich R, Sandhoff R, Jennemann R, Kraus FV, Tykocinski
L, Eckstein V, et al: Effect of increased lactate dehydrogenase a
activity and aerobic glycolysis on the proinflammatory profile of
autoimmune CD8+ T cells in rheumatoid arthritis. Arthritis
Rheumatol. 72:2050–2064. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brooks GA: Lactate shuttles in nature.
Biochem Soc Trans. 30:258–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brooks GA: Cell-cell and intracellular
lactate shuttles. J Physiol. 587(Pt 23): 5591–5600. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang C, Pan RY, Guan F and Yuan Z: Lactate
metabolism in neurodegenerative diseases. Neural Regen Res.
19:69–74. 2024. View Article : Google Scholar
|
|
9
|
Li X, Yang Y, Zhang B, Lin X, Fu X, An Y,
Zou Y, Wang JX, Wang Z and Yu T: Lactate metabolism in human health
and disease. Signal Transduct Target Ther. 7:3052022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gaffney DO, Jennings EQ, Anderson CC,
Marentette JO, Shi T, Schou Oxvig AM, Streeter MD, Johannsen M,
Spiegel DA, Chapman E, et al: Non-enzymatic lysine lactoylation of
glycolytic enzymes. Cell Chem Biol. 27:206–213.e6. 2020. View Article : Google Scholar :
|
|
11
|
Yao S, Yang X, An J, Jin H, Wen G, Wang H
and Tuo B: Role of the S100 protein family in liver disease
(Review). Int J Mol Med. 48:1662021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang JH, Toita R and Murata M: Liver
cell-targeted delivery of therapeutic molecules. Crit Rev
Biotechnol. 36:132–143. 2016. View Article : Google Scholar
|
|
13
|
Gao B: Hepatoprotective and
anti-inflammatory cytokines in alcoholic liver disease. J
Gastroenterol Hepatol. 27(Suppl 2): S89–S93. 2012. View Article : Google Scholar
|
|
14
|
Asrani SK, Devarbhavi H, Eaton J and
Kamath PS: Burden of liver diseases in the world. J Hepatol.
70:151–171. 2019. View Article : Google Scholar
|
|
15
|
Paik JM, Golabi P, Younossi Y, Mishra A
and Younossi ZM: Changes in the global burden of chronic liver
diseases from 2012 to 2017: The growing impact of NAFLD.
Hepatology. 72:1605–1616. 2020. View Article : Google Scholar
|
|
16
|
van Hall G: Lactate kinetics in human
tissues at rest and during exercise. Acta Physiol (Oxf).
199:499–508. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Feron O: Pyruvate into lactate and back:
From the Warburg effect to symbiotic energy fuel exchange in cancer
cells. Radiother Oncol. 92:329–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Bari L, Atlante A, Guaragnella N,
Principato G and Passarella S: D-Lactate transport and metabolism
in rat liver mitochondria. Biochem J. 365(Pt 2): 391–403. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bennis Y, Bodeau S, Batteux B,
Gras-Champel V, Masmoudi K, Maizel J, De Broe ME, Lalau JD and
Lemaire-Hurtel AS: A study of associations between plasma metformin
concentration, lactic acidosis, and mortality in an emergency
hospitalization context. Crit Care Med. 48:e1194–e1202. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jha MK, Lee IK and Suk K: Metabolic
reprogramming by the pyruvate dehydrogenase kinase-lactic acid
axis: Linking metabolism and diverse neuropathophysiologies.
Neurosci Biobehav Rev. 68:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Soreze Y, Boutron A, Habarou F, Barnerias
C, Nonnenmacher L, Delpech H, Mamoune A, Chrétien D, Hubert L,
Bole-Feysot C, et al: Mutations in human lipoyltransferase gene
LIPT1 cause a Leigh disease with secondary deficiency for pyruvate
and alpha-ketoglutarate dehydrogenase. Orphanet J Rare Dis.
8:1922013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Emhoff CA, Messonnier LA, Horning MA,
Fattor JA, Carlson TJ and Brooks GA: Gluconeogenesis and hepatic
glycogenolysis during exercise at the lactate threshold. J Appl
Physiol (1985). 114:297–306. 2013. View Article : Google Scholar
|
|
23
|
Wang T, Chen K, Yao W, Zheng R, He Q, Xia
J, Li J, Shao Y, Zhang L, Huang L, et al: Acetylation of lactate
dehydrogenase B drives NAFLD progression by impairing lactate
clearance. J Hepatol. 74:1038–1052. 2021. View Article : Google Scholar
|
|
24
|
Brown TP and Ganapathy V: Lactate/GPR81
signaling and proton motive force in cancer: Role in angiogenesis,
immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther.
206:1074512020. View Article : Google Scholar
|
|
25
|
Felmlee MA, Jones RS, Rodriguez-Cruz V,
Follman KE and Morris ME: Monocarboxylate transporters (SLC16):
Function, regulation, and role in health and disease. Pharmacol
Rev. 72:466–485. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Halestrap AP: The SLC16 gene
family-structure, role and regulation in health and disease. Mol
Aspects Med. 34:337–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun S, Li H, Chen J and Qian Q: Lactic
Acid: No longer an inert and end-product of glycolysis. Physiology
(Bethesda). 32:453–463. 2017.PubMed/NCBI
|
|
28
|
Contreras-Baeza Y, Sandoval PY, Alarcón R,
Galaz A, Cortés-Molina F, Alegría K, Baeza-Lehnert F, Arce-Molina
R, Guequén A, Flores CA, et al: Monocarboxylate transporter 4
(MCT4) is a high affinity transporter capable of exporting lactate
in high-lactate microenvironments. J Biol Chem. 294:20135–20147.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Halestrap AP: Monocarboxylic acid
transport. Compr Physiol. 3:1611–1643. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Valença I, Ferreira AR, Correia M, Kühl S,
van Roermund C, Waterham HR, Máximo V, Islinger M and Ribeiro D:
Prostate cancer proliferation is affected by the subcellular
localization of MCT2 and accompanied by significant peroxisomal
alterations. Cancers (Basel). 12:31522020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang G, Zhang Y, Dong D, Wang F, Ma X,
Guan F and Sun L: MCT1 regulates aggressive and metabolic
phenotypes in bladder cancer. J Cancer. 9:2492–2501. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Halestrap AP: The monocarboxylate
transporter family-Structure and functional characterization. IUBMB
Life. 64:1–9. 2012. View Article : Google Scholar
|
|
33
|
Droździk M, Szeląg-Pieniek S,
Grzegółkowska J, Łapczuk-Romańska J, Post M, Domagała P,
Miętkiewski J, Oswald S and Kurzawski M: Monocarboxylate
transporter 1 (MCT1) in liver pathology. Int J Mol Sci.
21:16062020. View Article : Google Scholar
|
|
34
|
Min K, Yenilmez B, Kelly M, Echeverria D,
Elleby M, Lifshitz LM, Raymond N, Tsagkaraki E, Harney SM, DiMarzio
C, et al: Lactate transporter MCT1 in hepatic stellate cells
promotes fibrotic collagen expression in nonalcoholic
steatohepatitis. bioRxiv [Preprint] 2023.05.03.539244. 2023.
|
|
35
|
Martini T, Ripperger JA, Chavan R, Stumpe
M, Netzahualcoyotzi C, Pellerin L and Albrecht U: The hepatic
monocarboxylate transporter 1 (MCT1) contributes to the regulation
of food anticipation in mice. Front Physiol. 12:6654762021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Carneiro L, Asrih M, Repond C, Sempoux C,
Stehle JC, Leloup C, Jornayvaz FR and Pellerin L: AMPK activation
caused by reduced liver lactate metabolism protects against hepatic
steatosis in MCT1 haploinsufficient mice. Mol Metab. 6:1625–1633.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lengacher S, Nehiri-Sitayeb T, Steiner N,
Carneiro L, Favrod C, Preitner F, Thorens B, Stehle JC, Dix L,
Pralong F, et al: Resistance to diet-induced obesity and associated
metabolic perturbations in haploinsufficient monocarboxylate
transporter 1 mice. PLoS One. 8:e825052013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fan Q, Yang L, Zhang X, Ma Y, Li Y, Dong
L, Zong Z, Hua X, Su D, Li H and Liu J: Autophagy promotes
metastasis and glycolysis by upregulating MCT1 expression and
Wnt/β-catenin signaling pathway activation in hepatocellular
carcinoma cells. J Exp Clin Cancer Res. 37:92018. View Article : Google Scholar
|
|
39
|
Gao HJ, Zhao MC, Zhang YJ, Zhou DS, Xu L,
Li GB, Chen MS and Liu J: Monocarboxylate transporter 4 predicts
poor prognosis in hepatocellular carcinoma and is associated with
cell proliferation and migration. J Cancer Res Clin Oncol.
141:1151–1162. 2015. View Article : Google Scholar
|
|
40
|
Chen HL, OuYang HY, Le Y, Jiang P, Tang H,
Yu ZS, He MK, Tang YQ and Shi M: Aberrant MCT4 and GLUT1 expression
is correlated with early recurrence and poor prognosis of
hepatocellular carcinoma after hepatectomy. Cancer Med.
7:5339–5350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Niu Z, Yang F, Li H, Wang J, Ni Q, Ma C,
Zhu H, Chang H, Zhou X, Lu J and Gao H: MCT4 promotes
hepatocellular carcinoma progression by upregulating TRAPPC5 gene.
J Hepatocell Carcinoma. 9:289–300. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao Y, Li W, Li M, Hu Y, Zhang H, Song G,
Yang L, Cai K and Luo Z: Targeted inhibition of MCT4 disrupts
intracellular pH homeostasis and confers self-regulated apoptosis
on hepatocellular carcinoma. Exp Cell Res. 384:1115912019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhou J, Shao Q, Lu Y, Li Y, Xu Z, Zhou B,
Chen Q, Li X, Xu X, Pan Y, et al: Monocarboxylate transporter
upregulation in induced regulatory T cells promotes resistance to
anti-PD-1 therapy in hepatocellular carcinoma patients. Front
Oncol. 12:9600662022. View Article : Google Scholar
|
|
44
|
Hu J, Cai M, Liu Y, Liu B, Xue X, Ji R,
Bian X and Lou S: The roles of GRP81 as a metabolic sensor and
inflammatory mediator. J Cell Physiol. 235:8938–8950. 2020.
View Article : Google Scholar
|
|
45
|
Hoque R, Farooq A, Ghani A, Gorelick F and
Mehal WZ: Lactate reduces liver and pancreatic injury in Toll-like
receptorand inflammasome-mediated inflammation via GPR81-mediated
suppression of innate immunity. Gastroenterology. 146:1763–1774.
2014. View Article : Google Scholar
|
|
46
|
Ahmed K, Tunaru S, Tang C, Müller M, Gille
A, Sassmann A, Hanson J and Offermanns S: An autocrine lactate loop
mediates insulin-dependent inhibition of lipolysis through GPR81.
Cell Metab. 11:311–319. 2010. View Article : Google Scholar
|
|
47
|
Wu G, Dai Y, Yan Y, Zheng X, Zhang H, Li H
and Chen W: The lactate receptor GPR81 mediates hepatic lipid
metabolism and the therapeutic effect of metformin on experimental
NAFLDs. Eur J Pharmacol. 924:1749592022. View Article : Google Scholar
|
|
48
|
Hui S, Ghergurovich JM, Morscher RJ, Jang
C, Teng X, Lu W, Esparza LA, Reya T, Le Zhan, Yanxiang Guo J, et
al: Glucose feeds the TCA cycle via circulating lactate. Nature.
551:115–118. 2017. View Article : Google Scholar
|
|
49
|
Dienel GA: Brain glucose metabolism:
Integration of energetics with function. Physiol Rev. 99:949–1045.
2019. View Article : Google Scholar
|
|
50
|
Lhomme T, Clasadonte J, Imbernon M,
Fernandois D, Sauve F, Caron E, da Silva Lima N, Heras V,
Martinez-Corral I, Mueller-Fielitz H, et al: Tanycytic networks
mediate energy balance by feeding lactate to glucose-insensitive
POMC neurons. J Clin Invest. 131:e1405212021. View Article : Google Scholar
|
|
51
|
Gómez-Valadés AG, Pozo M, Varela L,
Boudjadja MB, Ramírez S, Chivite I, Eyre E, Haddad-Tóvolli R, Obri
A, Milà-Guasch M, et al: Mitochondrial cristae-remodeling protein
OPA1 in POMC neurons couples Ca(2+) homeostasis with adipose tissue
lipolysis. Cell Metab. 33:1820–1835.e9. 2021. View Article : Google Scholar
|
|
52
|
Faubert B, Li KY, Cai L, Hensley CT, Kim
J, Zacharias LG, Yang C, Do QN, Doucette S, Burguete D, et al:
Lactate metabolism in human lung tumors. Cell. 171:358–371.e9.
2017. View Article : Google Scholar
|
|
53
|
Pucino V, Certo M, Bulusu V, Cucchi D,
Goldmann K, Pontarini E, Haas R, Smith J, Headland SE, Blighe K, et
al: Lactate buildup at the site of chronic inflammation promotes
disease by inducing CD4(+) T cell metabolic rewiring. Cell Metab.
30:1055–1074.e8. 2019. View Article : Google Scholar
|
|
54
|
Irizarry-Caro RA, McDaniel MM, Overcast
GR, Jain VG, Troutman TD and Pasare C: TLR signaling adapter BCAP
regulates inflammatory to reparatory macrophage transition by
promoting histone lactylation. Proc Natl Acad Sci USA.
117:30628–30638. 2020. View Article : Google Scholar
|
|
55
|
Rho H, Terry AR, Chronis C and Hay N:
Hexokinase 2-mediated gene expression via histone lactylation is
required for hepatic stellate cell activation and liver fibrosis.
Cell Metab. 35:1406–1423.e8. 2023. View Article : Google Scholar
|
|
56
|
Yang Z, Yan C, Ma J, Peng P, Ren X, Cai S,
Shen X, Wu Y, Zhang S, Wang X, et al: Lactylome analysis suggests
lactylation-dependent mechanisms of metabolic adaptation in
hepatocellular carcinoma. Nat Metab. 5:61–79. 2023. View Article : Google Scholar
|
|
57
|
Pan L, Feng F, Wu J, Fan S, Han J, Wang S,
Yang L, Liu W, Wang C and Xu K: Demethylzeylasteral targets lactate
by inhibiting histone lactylation to suppress the tumorigenicity of
liver cancer stem cells. Pharmacol Res. 181:1062702022. View Article : Google Scholar
|
|
58
|
Hayes C, Donohoe CL, Davern M and Donlon
NE: The oncogenic and clinical implications of lactate induced
immunosuppression in the tumour microenvironment. Cancer Lett.
500:75–86. 2021. View Article : Google Scholar
|
|
59
|
Li Y, Mo H, Wu S, Liu X and Tu K: A novel
lactate metabolism-related gene signature for predicting clinical
outcome and tumor microenvironment in hepatocellular carcinoma.
Front Cell Dev Biol. 9:8019592022. View Article : Google Scholar
|
|
60
|
Yang L, Tan P, Sun H, Zeng Z and Pan Y:
Integrative dissection of novel lactate metabolism-related
signature in the tumor immune microenvironment and prognostic
prediction in breast cancer. Front Oncol. 12:8747312022. View Article : Google Scholar
|
|
61
|
Wang Z, Zhang S, Li J, Yuan Y, Chen S, Zuo
M, Li W, Feng W, Chen M and Liu Y: Prognostic value of lactate
metabolism-related gene expression signature in adult primary
gliomas and its impact on the tumor immune microenvironment. Front
Oncol. 12:10082192022. View Article : Google Scholar
|
|
62
|
Zhang D, Tang Z, Huang H, Zhou G, Cui C,
Weng Y, Liu W, Kim S, Lee S, Perez-Neut M, et al: Metabolic
regulation of gene expression by histone lactylation. Nature.
574:575–580. 2019. View Article : Google Scholar
|
|
63
|
Izzo LT and Wellen KE: Histone lactylation
links metabolism and gene regulation. Nature. 574:492–493. 2019.
View Article : Google Scholar
|
|
64
|
Oosterveer MH and Schoonjans K: Hepatic
glucose sensing and integrative pathways in the liver. Cell Mol
Life Sci. 71:1453–1467. 2014. View Article : Google Scholar
|
|
65
|
Lei Y, Han P, Chen Y, Wang H, Wang S, Wang
M, Liu J, Yan W, Tian D and Liu M: Protein arginine
methyltransferase 3 promotes glycolysis and hepatocellular
carcinoma growth by enhancing arginine methylation of lactate
dehydrogenase A. Clin Transl Med. 12:e6862022. View Article : Google Scholar
|
|
66
|
Lazzeri C, Gensini GF, Sori A, Bernardo P,
Chiostri M, Tommasi E, Grossi F and Valente S: Dynamic behaviour of
lactate values during mild hypothermia in patients with cardiac
arrest. Eur Heart J Acute Cardiovasc Care. 3:176–182. 2014.
View Article : Google Scholar
|
|
67
|
Scheiner B, Lindner G, Reiberger T,
Schneeweiss B, Trauner M, Zauner C and Funk GC: Acid-base disorders
in liver disease. J Hepatol. 67:1062–1073. 2017. View Article : Google Scholar
|
|
68
|
Drolz A, Horvatits T, Rutter K, Landahl F,
Roedl K, Meersseman P, Wilmer A, Kluwe J, Lohse AW, Kluge S, et al:
Lactate improves prediction of short-term mortality in Critically
Ill patients with cirrhosis: A multinational study. Hepatology.
69:258–269. 2019. View Article : Google Scholar
|
|
69
|
Gao Y, Zhang H, Zhong H, Yang S and Wang
Q: Lactate and blood ammonia on admission as biomarkers to predict
the prognosis of patients with acute mushroom poisoning and liver
failure: A retrospective study. Toxicol Res (Camb). 10:850–855.
2021. View Article : Google Scholar
|
|
70
|
Roehlen N, Crouchet E and Baumert TF:
Liver fibrosis: Mechanistic concepts and therapeutic perspectives.
Cells. 9:8752020. View Article : Google Scholar
|
|
71
|
Dulai PS, Singh S, Patel J, Soni M, Prokop
LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, et al:
Increased risk of mortality by fibrosis stage in nonalcoholic fatty
liver disease: Systematic review and meta-analysis. Hepatology.
65:1557–1565. 2017. View Article : Google Scholar
|
|
72
|
Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y,
Yao Y and Ye T: Liver fibrosis: Therapeutic targets and advances in
drug therapy. Front Cell Dev Biol. 9:7301762021. View Article : Google Scholar
|
|
73
|
Sherman MH: Stellate cells in tissue
repair, inflammation, and cancer. Annu Rev Cell Dev Biol.
34:333–355. 2018. View Article : Google Scholar
|
|
74
|
Mejias M, Gallego J, Naranjo-Suarez S,
Ramirez M, Pell N, Manzano A, Suñer C, Bartrons R, Mendez R and
Fernandez M: CPEB4 increases expression of PFKFB3 to induce
glycolysis and activate mouse and human hepatic stellate cells,
promoting liver fibrosis. Gastroenterology. 159:273–288. 2020.
View Article : Google Scholar
|
|
75
|
Trivedi P, Wang S and Friedman SL: The
power of plasticity-metabolic regulation of hepatic stellate cells.
Cell Metab. 33:242–257. 2021. View Article : Google Scholar
|
|
76
|
Shangguan X, He J, Ma Z, Zhang W, Ji Y,
Shen K, Yue Z, Li W, Xin Z, Zheng Q, et al: SUMOylation controls
the binding of hexokinase 2 to mitochondria and protects against
prostate cancer tumorigenesis. Nat Commun. 12:18122021. View Article : Google Scholar
|
|
77
|
Riazi K, Azhari H, Charette JH, Underwood
FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG and Shaheen
AA: The prevalence and incidence of NAFLD worldwide: A systematic
review and meta-analysis. Lancet Gastroenterol Hepatol. 7:851–861.
2022. View Article : Google Scholar
|
|
78
|
Estes C, Razavi H, Loomba R, Younossi Z
and Sanyal AJ: Modeling the epidemic of nonalcoholic fatty liver
disease demonstrates an exponential increase in burden of disease.
Hepatology. 67:123–133. 2018. View Article : Google Scholar
|
|
79
|
Afonso MB, Rodrigues PM, Simão AL and
Castro RE: Circulating microRNAs as potential biomarkers in
non-alcoholic fatty liver disease and hepatocellular carcinoma. J
Clin Med. 5:302016. View Article : Google Scholar
|
|
80
|
Jeppesen JB, Mortensen C, Bendtsen F and
Møller S: Lactate metabolism in chronic liver disease. Scand J Clin
Lab Invest. 73:293–299. 2013. View Article : Google Scholar
|
|
81
|
Ha TS, Shin TG, Jo IJ, Hwang SY, Chung CR,
Suh GY and Jeon K: Lactate clearance and mortality in septic
patients with hepatic dysfunction. Am J Emerg Med. 34:1011–1015.
2016. View Article : Google Scholar
|
|
82
|
Li J, Wang T, Xia J, Yao W and Huang F:
Enzymatic and nonenzymatic protein acetylations control glycolysis
process in liver diseases. FASEB J. 33:11640–11654. 2019.
View Article : Google Scholar
|
|
83
|
Vazquez JH, Kennon-McGill S, Byrum SD,
Mackintosh SG, Jaeschke H, Williams DK, Lee WM, Dranoff JA and
McGill MR; Acute Liver Failure Study Group: Proteomics indicates
lactate dehydrogenase is prognostic in acetaminophen-induced acute
liver failure patients and reveals altered signaling pathways.
Toxicol Sci. 187:25–34. 2022. View Article : Google Scholar
|
|
84
|
Bernal W, Donaldson N, Wyncoll D and
Wendon J: Blood lactate as an early predictor of outcome in
paracetamol-induced acute liver failure: A cohort study. Lancet.
359:558–563. 2002. View Article : Google Scholar
|
|
85
|
Macquillan GC, Seyam MS, Nightingale P,
Neuberger JM and Murphy N: Blood lactate but not serum phosphate
levels can predict patient outcome in fulminant hepatic failure.
Liver Transpl. 11:1073–1079. 2005. View Article : Google Scholar
|
|
86
|
Dabos KJ, Newsome PN, Parkinson JA,
Davidson JS, Sadler IH, Plevris JN and Hayes PC: A biochemical
prognostic model of outcome in paracetamol-induced acute liver
injury. Transplantation. 80:1712–1717. 2005. View Article : Google Scholar
|
|
87
|
Schmidt LE and Larsen FS: Prognostic
implications of hyperlactatemia, multiple organ failure, and
systemic inflammatory response syndrome in patients with
acetaminophen-induced acute liver failure. Crit Care Med.
34:337–343. 2006. View Article : Google Scholar
|
|
88
|
Cholongitas EB, Betrossian A, Leandro G,
Shaw S, Patch D and Burroughs AK: King's criteria, APACHE II, and
SOFA scores in acute liver failure. Hepatology. 43:881author reply
882. 2006. View Article : Google Scholar
|
|
89
|
Gow PJ, Warrilow S, Lontos S, Lubel J,
Wongseelashote S, MacQuillan GC, Jones RM, Bellomo R and Angus PW:
Time to review the selection criteria for transplantation in
paracetamol-induced fulminant hepatic failure? Liver Transpl.
13:1762–1763. 2007. View Article : Google Scholar
|
|
90
|
Agrawal T, Maiwall R, Rajan V, Bajpai M,
Jagdish RK, Sarin SK and Trehanpati N: Higher circulating natural
killer cells and lower lactate levels at admission predict
spontaneous survival in non-acetaminophen induced acute liver
failure. Clin Immunol. 231:1088292021. View Article : Google Scholar
|
|
91
|
Karvellas CJ, Tillman H, Leung AA, Lee WM,
Schilsky ML, Hameed B, Stravitz RT, McGuire BM and Fix OK; United
States Acute Liver Failure Study Group: Acute liver injury and
acute liver failure from mushroom poisoning in North America. Liver
Int. 36:1043–1050. 2016. View Article : Google Scholar
|
|
92
|
Feldman AG, Sokol RJ, Hardison RM, Alonso
EM, Squires RH and Narkewicz MR; Pediatric Acute Liver Failure
Study Group: Lactate and Lactate: Pyruvate ratio in the diagnosis
and outcomes of pediatric acute liver failure. J Pediatr.
182:217–222.e3. 2017. View Article : Google Scholar
|
|
93
|
Haidar MK, Morton N, Roederer T, Mayronne
S, Bawo L, Kerkula J, Porten K and Baud FJ: Evaluating lactate
prognostic value in children suspected of acetaminophen-induced
liver failure in Liberia. Pediatr Res. 88:605–611. 2020. View Article : Google Scholar
|
|
94
|
Schmidt LE and Larsen FS: Is lactate
concentration of major value in determining the prognosis in
patients with acute liver failure? Hardly. J Hepatol. 53:211–212.
2010. View Article : Google Scholar
|
|
95
|
Bernal W: Lactate is important in
determining prognosis in acute liver failure. J Hepatol.
53:209–210. 2010. View Article : Google Scholar
|
|
96
|
Niederwieser T, Braunwarth E, Dasari BVM,
Pufal K, Szatmary P, Hackl H, Haselmann C, Connolly CE, Cardini B,
Öfner D, et al: Early postoperative arterial lactate concentrations
to stratify risk of post-hepatectomy liver failure. Br J Surg.
108:1360–1370. 2021. View Article : Google Scholar
|
|
97
|
Popescu M, Dima S, Brasoveanu V, Tudor A,
Simionescu M and Tomescu D: High perioperative lactate levels and
decreased lactate clearance are associated with increased incidence
of posthepatectomy liver failure. Hepatobiliary Pancreat Dis Int.
20:592–594. 2021. View Article : Google Scholar
|
|
98
|
Gao F, Huang XL, Cai MX, Lin MT, Wang BF,
Wu W and Huang ZM: Prognostic value of serum lactate kinetics in
critically ill patients with cirrhosis and acute-on-chronic liver
failure: A multicenter study. Aging (Albany NY). 11:4446–4462.
2019. View Article : Google Scholar
|
|
99
|
Cardoso FS, Abraldes JG, Sy E, Ronco JJ,
Bagulho L, Mcphail MJ and Karvellas CJ: Lactate and number of organ
failures predict intensive care unit mortality in patients with
acute-on-chronic liver failure. Liver Int. 39:1271–1280. 2019.
View Article : Google Scholar
|
|
100
|
Kotoh K, Kato M, Kohjima M, Tanaka M,
Miyazaki M, Nakamura K, Enjoji M, Nakamuta M and Takayanagi R:
Lactate dehydrogenase production in hepatocytes is increased at an
early stage of acute liver failure. Exp Ther Med. 2:195–199. 2011.
View Article : Google Scholar
|
|
101
|
Cassidy WM and Reynolds TB: Serum lactic
dehydrogenase in the differential diagnosis of acute hepatocellular
injury. J Clin Gastroenterol. 19:118–121. 1994. View Article : Google Scholar
|
|
102
|
Krispin I, Mahamid M, Goldin E and Fteiha
B: Elevated lactate/albumin ratio as a novel predictor of
in-hospital mortality in hospitalized cirrhotics. Ann Hepatol.
28:1008972023. View Article : Google Scholar
|
|
103
|
Nie Y, Liu LX, Chen T, Zhang Y and Zhu X:
Serum lactate level predicts 6-months mortality in patients with
hepatitis B virus-related decompensated cirrhosis: A retrospective
study. Epidemiol Infect. 149:e262021. View Article : Google Scholar
|
|
104
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar
|
|
105
|
Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N
and Zhao Y: Recent progress in treatment of hepatocellular
carcinoma. Am J Cancer Res. 10:2993–3036. 2020.
|
|
106
|
Hanahan D and Coussens LM: Accessories to
the crime: Functions of cells recruited to the tumor
microenvironment. Cancer Cell. 21:309–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Lee DC, Sohn HA, Park ZY, Oh S, Kang YK,
Lee KM, Kang M, Jang YJ, Yang SJ, Hong YK, et al: A lactate-induced
response to hypoxia. Cell. 161:595–609. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Deng H, Kan A, Lyu N, He M, Huang X, Qiao
S, Li S, Lu W, Xie Q, Chen H, et al: Tumor-derived lactate inhibit
the efficacy of lenvatinib through regulating PD-L1 expression on
neutrophil in hepatocellular carcinoma. J Immunother Cancer.
9:e0023052021. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Xu Y, Hao X, Ren Y, Xu Q, Liu X, Song S
and Wang Y: Research progress of abnormal lactate metabolism and
lactate modification in immunotherapy of hepatocellular carcinoma.
Front Oncol. 12:10634232022. View Article : Google Scholar
|
|
110
|
Tu CE, Hu Y, Zhou P, Guo X, Gu C, Zhang Y,
Li A and Liu S: Lactate and TGF-β antagonistically regulate
inflammasome activation in the tumor microenvironment. J Cell
Physiol. 236:4528–4537. 2021. View Article : Google Scholar
|
|
111
|
Apicella M, Giannoni E, Fiore S, Ferrari
KJ, Fernández-Pérez D, Isella C, Granchi C, Minutolo F, Sottile A,
Comoglio PM, et al: Increased lactate secretion by cancer cells
sustains non-cell-autonomous adaptive resistance to MET and EGFR
targeted therapies. Cell Metab. 28:848–65 e6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Huang X, Gan G, Wang X, Xu T and Xie W:
The HGF-MET axis coordinates liver cancer metabolism and autophagy
for chemotherapeutic resistance. Autophagy. 15:1258–1279. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Shan T, Chen S, Chen X, Wu T, Yang Y, Li
S, Ma J, Zhao J, Lin W, Li W, et al: M2-TAM subsets altered by
lactic acid promote T-cell apoptosis through the PD-L1/PD-1
pathway. Oncol Rep. 44:1885–1894. 2020.PubMed/NCBI
|
|
114
|
Lu LG, Zhou ZL, Wang XY, Liu BY, Lu JY,
Liu S, Zhang GB, Zhan MX and Chen Y: PD-L1 blockade liberates
intrinsic antitumourigenic properties of glycolytic macrophages in
hepatocellular carcinoma. Gut. 71:2551–2560. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Stone SC, Rossetti RAM, Alvarez KLF,
Carvalho JP, Margarido PFR, Baracat EC, Tacla M, Boccardo E,
Yokochi K, Lorenzi NP and Lepique AP: Lactate secreted by cervical
cancer cells modulates macrophage phenotype. J Leukoc Biol.
105:1041–1054. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Chu X, Di C, Chang P, Li L, Feng Z, Xiao
S, Yan X, Xu X, Li H, Qi R, et al: Lactylated histone H3K18 as a
potential biomarker for the diagnosis and predicting the severity
of septic shock. Front Immunol. 12:7866662022. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Suk FM, Wu CY, Fang CC, Chen TL and Liao
YJ: β-HB treatment reverses sorafenib resistance by shifting
glycolysis-lactate metabolism in HCC. Biomed Pharmacother.
166:1152932023. View Article : Google Scholar
|
|
118
|
Baltazar F, Afonso J, Costa M and Granja
S: Lactate beyond a waste metabolite: Metabolic affairs and
signaling in malignancy. Front Oncol. 10:2312020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Sheng SL, Liu JJ, Dai YH, Sun XG, Xiong XP
and Huang G: Knockdown of lactate dehydrogenase A suppresses tumor
growth and metastasis of human hepatocellular carcinoma. FEBS J.
279:3898–3910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Fukao T, Lopaschuk GD and Mitchell GA:
Pathways and control of ketone body metabolism: On the fringe of
lipid biochemistry. Prostaglandins Leukot Essent Fatty Acids.
70:243–251. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Li X, Lu P, Li B, Yang R, Chu Y, Zhang Z,
Wan H, Niu C, Wang C and Luo K: Sensitization of hepatocellular
carcinoma cells to irradiation by miR-34a through targeting lactate
dehydrogenase-A. Mol Med Rep. 13:3661–3667. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Zhang K, Mu L, Ding MC, Xu R, Ding ZJ and
Liang J: NFκB mediated elevation of KCNJ11 promotes tumor
progression of hepatocellular carcinoma through interaction of
lactate dehydrogenase A. Biochem Biophys Res Commun. 495:246–253.
2018. View Article : Google Scholar
|
|
123
|
Serra M, Di Matteo M, Serneels J, Pal R,
Cafarello ST, Lanza M, Sanchez-Martin C, Evert M, Castegna A,
Calvisi DF, et al: Deletion of lactate dehydrogenase-a impairs
oncogene-induced mouse hepatocellular carcinoma development. Cell
Mol Gastroenterol Hepatol. 14:609–624. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Cui W, Lv W, Qu Y, Ma R, Wang YW, Xu YJ,
Wu D and Chen X: Discovery of
2-((3-cyanopyridin-2-yl)thio)acetamides as human lactate
dehydrogenase A inhibitors to reduce the growth of MG-63
osteosarcoma cells: Virtual screening and biological validation.
Bioorg Med Chem Lett. 26:3984–3987. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Le A, Cooper CR, Gouw AM, Dinavahi R,
Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL and Dang
CV: Inhibition of lactate dehydrogenase A induces oxidative stress
and inhibits tumor progression. Proc Natl Acad Sci USA.
107:2037–2042. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Chen CY, Feng Y, Chen JY and Deng H:
Identification of a potent inhibitor targeting human lactate
dehydrogenase A and its metabolic modulation for cancer cell line.
Bioorg Med Chem Lett. 26:72–75. 2016. View Article : Google Scholar
|
|
127
|
McDonald B, Zucoloto AZ, Yu IL, Burkhard
R, Brown K, Geuking MB and McCoy KD: Programing of an intravascular
immune firewall by the gut microbiota protects against pathogen
dissemination during infection. Cell Host Microbe. 28:660–668.e4.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Han S, Bao X, Zou Y, Wang L, Li Y, Yang L,
Liao A, Zhang X, Jiang X, Liang D, et al: d-lactate modulates M2
tumor-associated macrophages and remodels immunosuppressive tumor
microenvironment for hepatocellular carcinoma. Sci Adv.
9:eadg26972023. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Chen Y, Bei J, Chen M, Cai W, Zhou Z, Cai
M, Huang W, Lin L, Guo Y, Liu M, et al: Intratumoral lactate
depletion based on injectable nanoparticles-hydrogel composite
system synergizes with immunotherapy against postablative
hepatocellular carcinoma recurrence. Adv Healthc Mater.
13:e23030312024. View Article : Google Scholar
|
|
130
|
Kubackova K, Bortlicek Z, Pavlik T,
Melichar B, Linke Z, Pokorna P, Vyzula R, Prausova J and Buchler T;
Czech Renal Cancer Cooperative Group: Prognostic factors in renal
cell carcinoma patients treated with sorafenib: Results from the
Czech registry. Target Oncol. 10:385–392. 2015. View Article : Google Scholar
|
|
131
|
Scartozzi M, Giampieri R, Maccaroni E, Del
Prete M, Faloppi L, Bianconi M, Galizia E, Loretelli C, Belvederesi
L, Bittoni A and Cascinu S: Pre-treatment lactate dehydrogenase
levels as predictor of efficacy of first-line bevacizumab-based
therapy in metastatic colorectal cancer patients. Br J Cancer.
106:799–804. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Hermes A, Gatzemeier U, Waschki B and Reck
M: Lactate dehydrogenase as prognostic factor in limited and
extensive disease stage small cell lung cancer-a retrospective
single institution analysis. Respir Med. 104:1937–1942. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Faloppi L, Scartozzi M, Bianconi M,
Svegliati Baroni G, Toniutto P, Giampieri R, Del Prete M, De
Minicis S, Bitetto D, Loretelli C, et al: The role of LDH serum
levels in predicting global outcome in HCC patients treated with
sorafenib: implications for clinical management. BMC Cancer.
14:1102014. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Sacco R, Mismas V, Granito A, Musettini G,
Masi G, Caparello C, Vivaldi C, Felder M, Bresci G and Fornaro L;
Italian Liver Cancer (IT.LI.CA) group: Correlation between LDH
levels and response to sorafenib in HCC patients: An analysis of
the ITA. LI.CA database. Int J Biol Markers. 30:e65–e72. 2015.
View Article : Google Scholar
|
|
135
|
Yada M, Miyazaki M, Motomura K, Masumoto
A, Nakamuta M, Kohjima M, Sugimoto R, Aratake Y, Higashi N,
Morizono S, et al: The prognostic role of lactate dehydrogenase
serum levels in patients with hepatocellular carcinoma who are
treated with sorafenib: the influence of liver fibrosis. J
Gastrointest Oncol. 7:615–623. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Wu SJ, Lin YX, Ye H, Xiong XZ, Li FY and
Cheng NS: Prognostic value of alkaline phosphatase, gamma-glutamyl
transpeptidase and lactate dehydrogenase in hepatocellular
carcinoma patients treated with liver resection. Int J Surg. 36(Pt
A): 143–151. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Gan Y, Gao F, Du B, Liu Y, Xue Q and Fu J:
Effects of preoperative serum lactate dehydrogenase levels on
long-term prognosis in elderly patients with hepatocellular
carcinoma undergoing transcatheter arterial chemoembolization.
Front Surg. 9:9821142022. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zhuang G, Xie Y, Hong J, Lin S, Chen T and
Fang W: Arterial chemoembolization for patients with hepatocellular
carcinoma and elevated lactate dehydrogenase is associated with low
survival: A cohort study. Infect Agent Cancer. 17:312022.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Su K, Huang W, Li X, Xu K, Gu T, Liu Y,
Song J, Qian K, Xu Y, Zeng H, et al: Evaluation of lactate
dehydrogenase and alkaline phosphatase as predictive biomarkers in
the prognosis of hepatocellular carcinoma and development of a new
nomogram. J Hepatocell Carcinoma. 10:69–79. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Cui Z, Li Y, Gao Y, Kong L, Lin Y and Chen
Y: Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular
carcinoma: A promising biomarker for early diagnosis, efficacy
evaluation and prognosis prediction. Aging (Albany NY).
12:19455–19467. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Jin J, Bai L, Wang D, Ding W, Cao Z, Yan
P, Li Y, Xi L, Wang Y, Zheng X, et al: SIRT3-dependent
delactylation of cyclin E2 prevents hepatocellular carcinoma
growth. EMBO Rep. 24:e560522023. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Cheng Z, Huang H, Li M, Liang X, Tan Y and
Chen Y: Lactylation-Related gene signature effectively predicts
prognosis and treatment responsiveness in hepatocellular carcinoma.
Pharmaceuticals (Basel). 16:6442023. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Doherty JR and Cleveland JL: Targeting
lactate metabolism for cancer therapeutics. J Clin Invest.
123:3685–3692. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Kooshki L, Mahdavi P, Fakhri S, Akkol EK
and Khan H: Targeting lactate metabolism and glycolytic pathways in
the tumor microenvironment by natural products: A promising
strategy in combating cancer. BioFactors. 48:359–383. 2022.
View Article : Google Scholar
|
|
145
|
Li Y, Zhou Y, Xia S, Chen L, Yang T, Zhao
D, Zhang Z, Shao J, Xu X, Zhang F and Zheng S: Blockade of
KLF5/LDH-A feedback loop contributes to Curcumol inhibition of
sinusoidal endothelial cell glycolysis and mitigation of liver
fibrosis. Phytomedicine. 114:1547592023. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Wang F, Chen L, Kong D, Zhang X, Xia S,
Liang B, Li Y, Zhou Y, Zhang Z, Shao J, et al: Canonical Wnt
signaling promotes HSC glycolysis and liver fibrosis through an
LDH-A/HIF-1α transcriptional complex. Hepatolog. 79:606–623. 2024.
View Article : Google Scholar
|
|
147
|
Ban D, Hua S, Zhang W, Shen C, Miao X and
Liu W: Costunolide reduces glycolysis-associated activation of
hepatic stellate cells via inhibition of hexokinase-2. Cell Mol
Biol Lett. 24:522019. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Reyes R, Wani NA, Ghoshal K, Jacob ST and
Motiwala T: Sorafenib and 2-deoxyglucose synergistically inhibit
proliferation of both sorafenib-sensitive and -resistant HCC cells
by inhibiting ATP production. Gene Expr. 17:129–140. 2017.
View Article : Google Scholar :
|
|
149
|
Tomizawa M, Shinozaki F, Motoyoshi Y,
Sugiyama T, Yamamoto S and Ishige N: 2-Deoxyglucose and sorafenib
synergistically suppress the proliferation and motility of
hepatocellular carcinoma cells. Oncol Lett. 13:800–804. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Raez LE, Papadopoulos K, Ricart AD,
Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ,
Tolba K, Langmuir VK, et al: A phase I dose-escalation trial of
2-deoxy-D-glucose alone or combined with docetaxel in patients with
advanced solid tumors. Cancer Chemother Pharmacol. 71:523–530.
2013. View Article : Google Scholar
|
|
151
|
Stein M, Lin H, Jeyamohan C, Dvorzhinski
D, Gounder M, Bray K, Eddy S, Goodin S, White E and Dipaola RS:
Targeting tumor metabolism with 2-deoxyglucose in patients with
castrate-resistant prostate cancer and advanced malignancies.
Prostate. 70:1388–1394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Sasaki K, Nishina S, Yamauchi A, Fukuda K,
Hara Y, Yamamura M, Egashira K and Hino K: Nanoparticle-Mediated
Delivery of 2-Deoxy-D-Glucose induces antitumor immunity and
cytotoxicity in liver tumors in mice. Cell Mol Gastroenterol
Hepatol. 11:739–762. 2021. View Article : Google Scholar :
|
|
153
|
Tomizawa M, Shinozaki F, Motoyoshi Y,
Sugiyama T, Yamamoto S and Ishige N: Suppressive effects of
3-bromopyruvate on the proliferation and the motility of
hepatocellular carcinoma cells. Oncol Rep. 35:59–63. 2016.
View Article : Google Scholar
|
|
154
|
Yoo JJ, Yu SJ, Na J, Kim K, Cho YY, Lee
YB, Cho EJ, Lee JH, Kim YJ, Youn H and Yoon JH: Hexokinase-II
inhibition synergistically augments the anti-tumor efficacy of
sorafenib in hepatocellular carcinoma. Int J Mol Sci. 20:12922019.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Sun X, Sun G, Huang Y, Hao Y, Tang X,
Zhang N, Zhao L, Zhong R and Peng Y: 3-Bromopyruvate regulates the
status of glycolysis and BCNU sensitivity in human hepatocellular
carcinoma cells. Biochem Pharmacol. 177:1139882020. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Wu H, Pan L, Gao C, Xu H, Li Y, Zhang L,
Ma L, Meng L, Sun X and Qin H: Quercetin inhibits the proliferation
of glycolysis-addicted HCC cells by reducing hexokinase 2 and
Akt-mTOR pathway. Molecules. 24:19932019. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Xu Q, Dou C, Liu X, Yang L, Ni C, Wang J,
Guo Y, Yang W, Tong X and Huang D: Oviductus ranae protein
hydrolysate (ORPH) inhibits the growth, metastasis and glycolysis
of HCC by targeting miR-491-5p/PKM2 axis. Biomed Pharmacother.
107:1692–1704. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Ferriero R, Nusco E, De Cegli R, Carissimo
A, Manco G and Brunetti-Pierri N: Pyruvate dehydrogenase complex
and lactate dehydrogenase are targets for therapy of acute liver
failure. J Hepatol. 69:325–335. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Billiard J, Dennison JB, Briand J, Annan
RS, Chai D, Colón M, Dodson CS, Gilbert SA, Greshock J, Jing J, et
al: Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and
reverse aerobic glycolysis in cancer cells. Cancer Metab. 1:192013.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Manerba M, Di Ianni L, Govoni M, Roberti
M, Recanatini M and Di Stefano G: LDH inhibition impacts on heat
shock response and induces senescence of hepatocellular carcinoma
cells. Eur J Pharm Sci. 105:91–98. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Payen VL, Mina E, Van Hée VF, Porporato PE
and Sonveaux P: Monocarboxylate transporters in cancer. Mol Metab.
33:48–66. 2020. View Article : Google Scholar :
|
|
162
|
Hadjihambi A, Konstantinou C, Klohs J,
Monsorno K, Le Guennec A, Donnelly C, Cox IJ, Kusumbe A, Hosford
PS, Soffientini U, et al: Partial MCT1 invalidation protects
against diet-induced non-alcoholic fatty liver disease and the
associated brain dysfunction. J Hepatol. 78:180–190. 2023.
View Article : Google Scholar
|
|
163
|
Jeon JY, Lee M, Whang SH, Kim JW, Cho A
and Yun M: Regulation of acetate utilization by monocarboxylate
transporter 1 (MCT1) in hepatocellular carcinoma (HCC). Oncol Res.
26:71–81. 2018. View Article : Google Scholar
|
|
164
|
Fang Y, Liu W, Tang Z, Ji X, Zhou Y, Song
S, Tian M, Tao C, Huang R, Zhu G, et al: Monocarboxylate
transporter 4 inhibition potentiates hepatocellular carcinoma
immunotherapy through enhancing T cell infiltration and immune
attack. Hepatology. 77:109–123. 2023. View Article : Google Scholar
|
|
165
|
Xu H, Li L, Wang S, Wang Z, Qu L, Wang C
and Xu K: Royal jelly acid suppresses hepatocellular carcinoma
tumorigenicity by inhibiting H3 histone lactylation at H3K9la and
H3K14la sites. Phytomedicine. 118:1549402023. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Zhou F, Shang W, Yu X and Tian J:
Glypican-3: A promising biomarker for hepatocellular carcinoma
diagnosis and treatment. Med Res Rev. 38:741–767. 2018. View Article : Google Scholar
|
|
167
|
Yao G and Yang Z: Glypican-3 knockdown
inhibits the cell growth, stemness, and glycolysis development of
hepatocellular carcinoma cells under hypoxic microenvironment
through lactylation. Arch Physiol Biochem. May 2–2023.Online ahead
of print. View Article : Google Scholar : PubMed/NCBI
|
